NZ603343A - Macrocyclic indole derivatives useful as hepatitis C virus inhibitors - Google Patents

Macrocyclic indole derivatives useful as hepatitis C virus inhibitors

Info

Publication number
NZ603343A
NZ603343A NZ603343A NZ60334309A NZ603343A NZ 603343 A NZ603343 A NZ 603343A NZ 603343 A NZ603343 A NZ 603343A NZ 60334309 A NZ60334309 A NZ 60334309A NZ 603343 A NZ603343 A NZ 603343A
Authority
NZ
New Zealand
Prior art keywords
hepatitis
indole derivatives
derivatives useful
virus inhibitors
macrocyclic indole
Prior art date
Application number
NZ603343A
Other languages
English (en)
Inventor
Sandrine Marie Helene Vendeville
Pierre Jean-Marie Bernard Raboisson
Tse-I Lin
Abdellah Tahri
Katie Ingrid Eduard Amssoms
Original Assignee
Janssen R & D Ireland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen R & D Ireland filed Critical Janssen R & D Ireland
Publication of NZ603343A publication Critical patent/NZ603343A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D515/18—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NZ603343A 2008-07-08 2009-07-08 Macrocyclic indole derivatives useful as hepatitis C virus inhibitors NZ603343A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP08159965 2008-07-08
EP08160254 2008-07-11
EP08161743 2008-08-04
NZ590073A NZ590073A (en) 2008-07-08 2009-07-08 Macrocyclic indole derivatives useful as hepatitis c virus inhibitors

Publications (1)

Publication Number Publication Date
NZ603343A true NZ603343A (en) 2013-08-30

Family

ID=40972916

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ603343A NZ603343A (en) 2008-07-08 2009-07-08 Macrocyclic indole derivatives useful as hepatitis C virus inhibitors
NZ590073A NZ590073A (en) 2008-07-08 2009-07-08 Macrocyclic indole derivatives useful as hepatitis c virus inhibitors

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ590073A NZ590073A (en) 2008-07-08 2009-07-08 Macrocyclic indole derivatives useful as hepatitis c virus inhibitors

Country Status (31)

Country Link
US (2) US8921355B2 (enExample)
EP (1) EP2310396B1 (enExample)
JP (2) JP5426671B2 (enExample)
KR (1) KR101640374B1 (enExample)
CN (1) CN102089314B (enExample)
AP (1) AP2743A (enExample)
AR (1) AR072726A1 (enExample)
AU (1) AU2009267389B8 (enExample)
BR (1) BRPI0915887B8 (enExample)
CA (1) CA2729307C (enExample)
CL (1) CL2011000032A1 (enExample)
CO (1) CO6351793A2 (enExample)
CR (1) CR20110076A (enExample)
DK (1) DK2310396T3 (enExample)
EA (1) EA019008B1 (enExample)
EC (1) ECSP11010750A (enExample)
ES (1) ES2651038T3 (enExample)
HN (1) HN2011000072A (enExample)
HR (1) HRP20171892T1 (enExample)
HU (1) HUE035244T2 (enExample)
IL (1) IL210086A (enExample)
LT (1) LT2310396T (enExample)
MX (1) MX2011000276A (enExample)
NI (1) NI201100010A (enExample)
NO (1) NO2310396T3 (enExample)
NZ (2) NZ603343A (enExample)
SI (1) SI2310396T1 (enExample)
SV (1) SV2011003796A (enExample)
TW (1) TWI454476B (enExample)
UY (1) UY31973A (enExample)
WO (1) WO2010003658A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8524716B2 (en) 2007-12-24 2013-09-03 Janssen R&D Ireland Macrocyclic indoles as hepatitis C virus inhibitors
TWI454476B (zh) * 2008-07-08 2014-10-01 Tibotec Pharm Ltd 用作ｃ型肝炎病毒抑制劑之巨環吲哚衍生物
UA108211C2 (uk) * 2009-11-04 2015-04-10 Янссен Рід Айрленд Бензімідазолімідазольні похідні
NZ602552A (en) * 2010-04-13 2014-09-26 Janssen Pharmaceuticals Inc Combination of a macrocyclic inhibitor of hcv, a non-nucleoside and a nucleoside
WO2011161232A1 (en) 2010-06-24 2011-12-29 Tibotec Pharmaceuticals PREPARATION OF 13-CYCLOHEXYL-3-METHOXY-6-[METHYL-(2-{2-[METHYL-(SULPHAMOYL)-AMINO]-ETHOXY}-ETHYL)-CARBAMOYL]-7H-INDOLO-[2,1-a]-[2]-BENZAZEPINE-10-CARBOXYLIC ACID
EP2760821B1 (en) 2011-09-02 2017-10-11 Novartis AG Choline salt of an anti-inflammatory substituted cyclobutenedione compound
US8716275B2 (en) * 2011-10-20 2014-05-06 Bristol-Myers Squibb Company Compound for the treatment of hepatitis C
KR20150046083A (ko) 2012-08-31 2015-04-29 얀센 파마슈티칼즈, 인코포레이티드 Ｈｃｖ의 거대환형 프로테아제 저해제, 비­뉴클레오시드계 ｈｃｖ 저해제 및 리토나비르의 조합물
WO2014152275A1 (en) * 2013-03-14 2014-09-25 Concert Pharmaceuticals, Inc. Deuterium modified derivatives of the ns5b polymerase inhibitor tmc647055
US10450263B2 (en) 2017-02-10 2019-10-22 Southern Research Institute Benzo annulenes as antiviral agents
KR101974388B1 (ko) 2017-06-23 2019-05-02 (주)에니켐텍 알킬 디에틸렌 트리아민 유도체 및 이의 제조방법
US11066357B2 (en) 2017-12-26 2021-07-20 Southern Research Institute Benzoannulene derivatives as antiviral agents
US12274700B1 (en) 2020-10-30 2025-04-15 Accencio LLC Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors
US12060148B2 (en) 2022-08-16 2024-08-13 Honeywell International Inc. Ground resonance detection and warning system and method
CN116425782A (zh) * 2023-03-22 2023-07-14 烟台盛凯伦化学科技有限公司 一种5-乙酰基-2-氟苯硼酸频哪醇酯的制备方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
US5807876A (en) 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
US6054472A (en) 1996-04-23 2000-04-25 Vertex Pharmaceuticals, Incorporated Inhibitors of IMPDH enzyme
US20050267836A1 (en) * 1996-03-25 2005-12-01 Cfph, Llc Method and system for transacting with a trading application
CZ298463B6 (cs) 1996-04-23 2007-10-10 Vertex Pharmaceuticals Incorporated Deriváty mocoviny pro použití jako inhibitory IMPDH enzymu a farmaceutické prostredky, které je obsahují
AU6701598A (en) 1997-03-14 1998-09-29 Vertex Pharmaceuticals Incorporated Inhibitors of impdh enzyme
SK13332001A3 (sk) 1999-03-19 2002-02-05 Vertex Pharmaceuticals Incorporated Inhibítory IMPDH enzýmu a ich použitie
US6891331B2 (en) 2000-08-30 2005-05-10 Matsushita Electric Industrial Co., Ltd. Plasma display unit and production method thereof
KR20120090077A (ko) 2004-01-30 2012-08-16 얀센 알 앤드 디 아일랜드 Ｈｃｖ ｎｓ?３ 세린 프로테아제 저해제
US7153848B2 (en) 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
RU2008112661A (ru) 2005-09-02 2009-10-10 Тиботек Фармасьютикалз Лтд. (Ie) Бензодиазепины в качестве ингибиторов hcv
US7399758B2 (en) 2005-09-12 2008-07-15 Meanwell Nicholas A Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
GB0522881D0 (en) 2005-11-10 2005-12-21 Angeletti P Ist Richerche Bio Therapeutic compounds
WO2007092000A1 (en) 2006-02-06 2007-08-16 Bristol-Myers Squibb Company Inhibitors of hcv replication
US7521443B2 (en) * 2006-05-17 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7456166B2 (en) 2006-05-17 2008-11-25 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7521441B2 (en) 2006-05-22 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
WO2007140200A2 (en) * 2006-05-25 2007-12-06 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
MX2009003452A (es) 2006-10-10 2009-04-14 Medivir Ab Inhibidores nucleosidicos del vhc.
CA2672250C (en) * 2006-12-20 2013-04-30 Ian Stansfield Antiviral indoles
JP2010533699A (ja) * 2007-07-17 2010-10-28 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー Ｃ型肝炎感染症の治療のための大環状インドール誘導体
TWI454476B (zh) 2008-07-08 2014-10-01 Tibotec Pharm Ltd 用作ｃ型肝炎病毒抑制劑之巨環吲哚衍生物
TW201023858A (en) 2008-09-18 2010-07-01 Ortho Mcneil Janssen Pharm Synergistic combinations of a macrocyclic inhibitor of HCV and a nucleoside
MX340792B (es) 2009-02-27 2016-07-25 Ortho-Mcneil-Janssen Pharmaceuticals Inc * Sal amorfa de un inhibidor macrociclico de virus de hepatitis c.
NZ602552A (en) 2010-04-13 2014-09-26 Janssen Pharmaceuticals Inc Combination of a macrocyclic inhibitor of hcv, a non-nucleoside and a nucleoside
WO2011161232A1 (en) 2010-06-24 2011-12-29 Tibotec Pharmaceuticals PREPARATION OF 13-CYCLOHEXYL-3-METHOXY-6-[METHYL-(2-{2-[METHYL-(SULPHAMOYL)-AMINO]-ETHOXY}-ETHYL)-CARBAMOYL]-7H-INDOLO-[2,1-a]-[2]-BENZAZEPINE-10-CARBOXYLIC ACID
KR20150046083A (ko) 2012-08-31 2015-04-29 얀센 파마슈티칼즈, 인코포레이티드 Ｈｃｖ의 거대환형 프로테아제 저해제, 비­뉴클레오시드계 ｈｃｖ 저해제 및 리토나비르의 조합물

Also Published As

Publication number Publication date
SI2310396T1 (en) 2018-01-31
CN102089314A (zh) 2011-06-08
CL2011000032A1 (es) 2011-07-15
LT2310396T (lt) 2017-12-27
AU2009267389B8 (en) 2013-07-04
CR20110076A (es) 2011-11-10
WO2010003658A1 (en) 2010-01-14
US9427440B2 (en) 2016-08-30
CA2729307A1 (en) 2010-01-14
TWI454476B (zh) 2014-10-01
AR072726A1 (es) 2010-09-15
JP5426671B2 (ja) 2014-02-26
TW201014865A (en) 2010-04-16
JP2014028818A (ja) 2014-02-13
ECSP11010750A (es) 2011-08-31
SV2011003796A (es) 2011-04-08
HUE035244T2 (hu) 2018-05-02
IL210086A (en) 2014-05-28
JP5808370B2 (ja) 2015-11-10
IL210086A0 (en) 2011-02-28
KR101640374B1 (ko) 2016-07-18
CN102089314B (zh) 2014-07-23
DK2310396T3 (en) 2017-12-11
US20110105473A1 (en) 2011-05-05
NZ590073A (en) 2012-11-30
EA019008B1 (ru) 2013-12-30
BRPI0915887B8 (pt) 2021-05-25
UY31973A (es) 2010-01-29
AP2010005521A0 (en) 2010-12-31
NO2310396T3 (enExample) 2018-02-03
ES2651038T3 (es) 2018-01-23
AU2009267389A1 (en) 2010-01-14
KR20110040889A (ko) 2011-04-20
HK1155734A1 (en) 2012-05-25
AU2009267389B2 (en) 2013-05-30
US8921355B2 (en) 2014-12-30
JP2011527299A (ja) 2011-10-27
CA2729307C (en) 2017-08-29
EP2310396B1 (en) 2017-09-06
EP2310396A1 (en) 2011-04-20
AU2009267389A8 (en) 2013-07-04
BRPI0915887B1 (pt) 2020-02-18
BRPI0915887A2 (pt) 2015-11-03
EA201170153A1 (ru) 2011-08-30
AP2743A (en) 2013-09-30
HRP20171892T1 (hr) 2018-01-12
HN2011000072A (es) 2013-09-01
NI201100010A (es) 2011-09-07
US20140107101A1 (en) 2014-04-17
CO6351793A2 (es) 2011-12-20
MX2011000276A (es) 2011-03-02

Similar Documents

Publication Publication Date Title
NZ590073A (en) Macrocyclic indole derivatives useful as hepatitis c virus inhibitors
TW200740776A (en) N-phenylbenzotriazolyl c-kit inhibitors
MX2009012595A (es) Derivados de espiroindolinona.
MX2009004920A (es) Nuevos derivados de aminopirimidina como inhibidores de plk1.
TW200716636A (en) Heterocyclic spiro-compounds
WO2009046841A8 (de) Piperidin- und piperazinderivate zur behandlung von tumoren
PH12013500363A1 (en) Use of substituted quinazoline compounds in treating age-related macular degeneration
IL189694A0 (en) Biphenyl derivatives and their use in treating hepatitis c
MEP0508A (xx) Derivati pirimidina
MY160424A (en) Substituted pyrrolidine-2-carboxyamides.
MY150542A (en) Cmet inhibitors
MY183039A (en) Pyridin-2-yl derivatives as immunomodulating agents
AU2006251620A8 (en) Imidazolone phenylalanine derivatives as VLA-4 antagonists
PH12012501125A1 (en) 3, 4, 4a, 10b - tetrahydro -1h- thiopyrano -[4, 3-c] isoquinoline derivatives
UA101018C2 (ru) Пирролопиримидинкарбоксамиды
PL2013279T3 (pl) Pochodne pirymidyn jako środki zmniejszające palność
IL206816A0 (en) Method for the production of 3,6-dihydro-1,3,5-triazine derivatives from metformin and paraldehyde derivatives
MY156955A (en) Antifungal agents
PL2300444T3 (pl) Sposób syntezy pochodnych 3,6-dihydro-1,3,5-triazyny
IL207064A0 (en) Novel 1,4-diaza-bicyclo[3.2.2]nonyl oxadiazolyl derivatives useful as modulator of nicotinic acetylcholine receptors
PL2331554T3 (pl) Makrocykliczne pochodne indolu użyteczne jako inhibitory wirusa zapalenia wątroby typu C
TW200738697A (en) Benzimidazole derivatives as 5-HT6,5-HT24
WO2009111028A8 (en) Aurora kinase inhibitors
TW200745110A (en) Naphthyridin derivatives
IL209732A0 (en) Salicylamide derivatives as nicotinic alpha 7 modulators

Legal Events

Date Code Title Description
S23 Proceedings under section 23: mention of inventor as such in patent

Free format text: INVENTOR AMSSOMS, KATIE, INGRID, EDUARD, TAHRI, ABDELLAH ADDED

Effective date: 20130905

PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 08 JUL 2016 BY CPA GLOBAL

Effective date: 20140113

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 08 JUL 2019 BY CPA GLOBAL

Effective date: 20140903

ASS Change of ownership

Owner name: JANSSEN SCIENCES IRELAND UC, IE

Effective date: 20150723

LAPS Patent lapsed